Patients' preferences for headache acute and preventive treatment

Several newer therapeutic formulations with more modern mechanisms are invited for the treatment of migraine and headache developed an explosive environment in the field of medicine. The patients’ perspectives and preferences should be taken into account while prescribing the medication. In this research, the author determines the patient preferences along with efficacy and safety data may help physicians to choose the right treatment for the right person. 

To examine patients' choices for headache therapies with a self-administered questionnaire involving the Q-No questionnaire for nocebo.

A total of 514 patients who naïve to neurostimulation and monoclonal antibodies have completed the questionnaires.

Patients focused on the treatment's efficacy rather than the route of administration or safety of the administrated drug. For both acute and preventive treatment, patients preferred an external neurostimulation device. For symptomatic pharmaceutical treatment, several patients opt for a pill than any other medication administered parenterally. For preventive pharmaceutical treatment, many of the patients go for a pill once per day (52%) than an injection either intravenously or subcutaneously every month, or three months. In Q-No questionnaire, 56.6% of out of all participants scored more than 15, showing potential nocebo behaviours that contributed considerably to their decisions.

The patient choices along with safety and efficacy information may assist physicians expertly choose the right therapy for the right person.